ES2520968T3 - Nuevo vector baculovírico - Google Patents

Nuevo vector baculovírico Download PDF

Info

Publication number
ES2520968T3
ES2520968T3 ES10193968.4T ES10193968T ES2520968T3 ES 2520968 T3 ES2520968 T3 ES 2520968T3 ES 10193968 T ES10193968 T ES 10193968T ES 2520968 T3 ES2520968 T3 ES 2520968T3
Authority
ES
Spain
Prior art keywords
dna sequence
acnpv
recombinant
promoter
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10193968.4T
Other languages
English (en)
Inventor
Shigeto Yoshida
Yoshio Ohba
Norimitsu Hariguchi
Masami Mizukoshi
Masanori Kawasaki
Makoto Matsumoto
Yoshihiro Goto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Jichi Medical University
Original Assignee
Otsuka Pharmaceutical Co Ltd
Jichi Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd, Jichi Medical University filed Critical Otsuka Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2520968T3 publication Critical patent/ES2520968T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • C12N2830/205—Vector systems having a special element relevant for transcription transcription of more than one cistron bidirectional
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composición farmacéutica que comprende un virus recombinante de la poliedrosis nuclear de Autographa californica (AcNPV), como un agente activo, y, opcionalmente, un vehículo farmacéuticamente aceptable, en la que el AcNPV recombinante contiene una estructura de secuencia de ADN que presenta una secuencia de ADN de fusión de (A) una secuencia de ADN que codifica PfCSP de la cepa 3D7 del parásito de la malaria P. falciparum, o su fragmento inmunógeno; y (B) una secuencia de ADN del nº de acceso L22858 de GenBank, que codifica los aminoácidos de la proteína gp64 de baculovirus, o un fragmento de la misma, que es capaz de ser el componente de la partícula vírica; bajo el control de un promotor dual que comprende el promotor de poliedrina y el promotor de CMV unidos entre sí.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34

Claims (1)

  1. imagen1
ES10193968.4T 2006-02-09 2007-02-08 Nuevo vector baculovírico Active ES2520968T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006032863 2006-02-09
JP2006032863 2006-02-09

Publications (1)

Publication Number Publication Date
ES2520968T3 true ES2520968T3 (es) 2014-11-12

Family

ID=38345218

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10193968.4T Active ES2520968T3 (es) 2006-02-09 2007-02-08 Nuevo vector baculovírico

Country Status (24)

Country Link
US (1) US9023365B2 (es)
EP (3) EP1983047A4 (es)
JP (1) JP4171930B2 (es)
KR (1) KR101472924B1 (es)
CN (2) CN103394096A (es)
AP (1) AP2880A (es)
AR (1) AR059422A1 (es)
AU (1) AU2007213030B2 (es)
BR (1) BRPI0707646A2 (es)
CA (1) CA2636632C (es)
CY (1) CY1115658T1 (es)
DK (2) DK2363462T3 (es)
ES (1) ES2520968T3 (es)
IL (3) IL192681A (es)
MX (1) MX2008010299A (es)
MY (1) MY144455A (es)
NO (1) NO20083376L (es)
PL (1) PL2363463T3 (es)
PT (1) PT2363463E (es)
RU (2) RU2453603C2 (es)
SI (1) SI2363463T1 (es)
TW (1) TWI477602B (es)
WO (1) WO2007091624A1 (es)
ZA (1) ZA200806144B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9333249B2 (en) 2006-02-09 2016-05-10 Educational Foundation Jichi Medical University Recombinant baculovirus vaccine
TWI477602B (zh) 2006-02-09 2015-03-21 Educational Foundation Jichi Medical Univ Novel viral vector
KR20100040947A (ko) * 2007-08-07 2010-04-21 각코우호우진 지치 이카다이가쿠 면역성 융합 유전자를 조절하는 척추동물 및 배큘로바이러스 이중 프로모터를 포함하는 배큘로바이러스 벡터
CA2731686C (en) 2008-07-25 2020-04-07 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
US20110201086A1 (en) * 2010-02-12 2011-08-18 Otsuka Pharmaceutical Co., Ltd. Method for producing recombinant virus
CN102234646B (zh) * 2010-04-23 2014-10-22 深圳华大基因科技有限公司 一种启动子SbUbi1、其制备方法及用途
US8557248B2 (en) 2010-08-09 2013-10-15 Cyvax, Inc. Methods and compositions for treating malaria
AU2011373387B2 (en) 2011-07-18 2017-06-29 Institute For Research In Biomedicine Neutralizing anti-influenza A virus antibodies and uses thereof
US9982239B2 (en) * 2012-06-12 2018-05-29 Alternative Gene Expression S.L. Baculoviral DNA elements for the expression of recombinant proteins in a host cell
WO2016059911A1 (ja) * 2014-10-17 2016-04-21 国立大学法人金沢大学 マラリアワクチン
CL2014003146A1 (es) * 2014-11-20 2015-06-12 Univ Santiago Chile Método para producir virus arn monocatenario negativo; plásmido recombinante funcional en células animales, que consta de un esqueleto pss-urg; método de obtención de partículas virales; y uso para expresar arn, proteínas autógenas o exógenas al virus.
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
RU2626590C2 (ru) * 2015-12-18 2017-07-28 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Генетическая конструкция для экспрессии генов в клетках насекомого polypedilum vanderplanki
CN105779499B (zh) * 2016-03-23 2019-11-19 江苏科技大学 重组杆状病毒和其应用及构建该重组杆状病毒的载体
CN110484657A (zh) * 2019-09-06 2019-11-22 广东省农业科学院植物保护研究所 检测斜纹夜蛾成虫带核型多角体病毒的巢式pcr引物、试剂盒及其方法
JP7649504B2 (ja) * 2022-02-18 2025-03-21 国立大学法人金沢大学 マラリアワクチン及びマラリア予防・治療方法
CN117305365B (zh) * 2023-11-28 2024-03-19 中国科学院生物物理研究所 昆虫细胞—哺乳动物细胞表达穿梭载体SmartBM-1及其应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
AU629554B2 (en) 1988-06-24 1992-10-08 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Exogenous gene expression vector containing chick beta-actin gene promoter
US5169784A (en) 1990-09-17 1992-12-08 The Texas A & M University System Baculovirus dual promoter expression vector
ES2370937T3 (es) 1993-09-13 2011-12-23 Protein Sciences Corporation Un método para producir vacunas antigripales polivalentes a base de hemaglutinina.
US5976552A (en) 1995-04-28 1999-11-02 Protein Sciences Corporation Virus vaccines
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
US6485729B1 (en) 1993-09-13 2002-11-26 Protein Sciences Corporation Neuraminidase-supplemented compositions
JP3090586B2 (ja) 1994-03-15 2000-09-25 片倉工業株式会社 システインプロテアーゼ遺伝子欠損バキュロウイルスおよびその製造法並びにこれを利用する有用タンパク質の製造法
GB9406492D0 (en) 1994-03-31 1994-05-25 Isis Innovation Malaria peptides
US6183993B1 (en) 1996-09-11 2001-02-06 The General Hospital Corporation Complement-resistant non-mammalian DNA viruses and uses thereof
WO1998011243A2 (en) 1996-09-11 1998-03-19 The General Hospital Corporation Expression of an exogenous gene in a mammalian cell by use of a non-mammalian dna virus having an altered coat protein
WO1998046262A1 (en) 1997-04-16 1998-10-22 Connaught Laboratories, Inc. Anti-influenza compositions supplemented with neuraminidase
GB9711578D0 (en) 1997-06-04 1997-07-30 Oxford Biomedica Ltd Novel retroviral vector production systems
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
US20030045492A1 (en) 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US20030125278A1 (en) 1997-08-13 2003-07-03 Tang De-Chu C. Immunization of animals by topical applications of a salmonella-based vector
US6716823B1 (en) 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
DE19735593C2 (de) 1997-08-15 1999-08-26 Hepavec Ag Fuer Gentherapie Hüllprotein-modifizierter Baculovirus-Vektor für die Gentherapie
US6103526A (en) 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
MXPA01011137A (es) 1999-05-03 2003-07-14 Uab Research Foundation Inmunizacion genetica no invasiva, productos de la expresion a partir de esta, y sus usos.
US20040009936A1 (en) 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
JP2003501042A (ja) 1999-05-27 2003-01-14 ジェノボ， インコーポレイテッド 非哺乳動物ウイルス由来のキャリアベクターを使用する、組換えウイルスの産生のための組成物および方法
US6793926B1 (en) 1999-05-27 2004-09-21 Genovo, Inc. Methods for production of a recombinant adeno-associated virus
US6589783B2 (en) * 2000-04-13 2003-07-08 Novagen, Inc. Multiple host expression vector
AU2001284791A1 (en) 2000-08-11 2002-02-25 Boyce Thompson Institute For Plant Research Inc. Gp64-null baculoviruses pseudotyped with heterologous envelope proteins
JP2002235236A (ja) 2000-12-05 2002-08-23 Kuraray Co Ltd ポリビニルアルコール系水溶性繊維
JPWO2002062381A1 (ja) 2001-02-05 2004-06-03 久光製薬株式会社 バキュロウイルスベクターワクチン
JP4655388B2 (ja) 2001-03-05 2011-03-23 富士レビオ株式会社 タンパク質の生産方法
US20030104965A1 (en) 2001-08-14 2003-06-05 Lonza Inc. Laundry sanitizer containing partially halogenated hydantoins
GB0119852D0 (en) 2001-08-15 2001-10-10 Univ York Baculovirus
WO2003020322A1 (de) 2001-09-04 2003-03-13 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Vektor zur induktion einer immunantwort
JP2003284557A (ja) 2002-03-25 2003-10-07 Alarvita Biolife Corp 新規バクロウィルス移入ベクターおよび外来遺伝子発現用の組換えバクロウィルス
US7416890B2 (en) 2002-09-25 2008-08-26 Osaka Industrial Promotion Organization Baculovirus vector, method of producing thereof and method of gene transfer
WO2004029259A1 (ja) 2002-09-25 2004-04-08 Osaka Industrial Promotion Organization バキュロウイルスベクター、バキュロウイルスベクター製造方法及び遺伝子導入方法
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
JP2005015346A (ja) 2003-06-23 2005-01-20 Hiroshi Takaku バキュロウイルス含有抗ウイルス剤
WO2005040388A2 (en) 2003-08-22 2005-05-06 Nucleonics Inc. Eukariotic expression systems for expression of inhibitory rna in multiple intracellular compartments
US7527967B2 (en) * 2003-11-25 2009-05-05 Academia Sinica Recombinant baculovirus and virus-like particle
GB0425739D0 (en) 2004-11-23 2004-12-22 Procure Therapeutics Ltd Humanised baculovirus 2
BRPI0615400A2 (pt) 2005-08-31 2011-05-17 Genvec Inc vacinas para malária baseadas em vetor adenoviral
JP2009001493A (ja) * 2005-09-27 2009-01-08 Nationa Hospital Organization Ｄｎａワクチン組成物
AP2008004448A0 (en) 2005-09-30 2008-04-30 Seattle Biomedical Res Inst Plasmodium liver stage antigens
TWI477602B (zh) 2006-02-09 2015-03-21 Educational Foundation Jichi Medical Univ Novel viral vector

Also Published As

Publication number Publication date
ZA200806144B (en) 2009-12-30
EP2363463A1 (en) 2011-09-07
RU2012108128A (ru) 2013-09-10
CA2636632A1 (en) 2007-08-16
WO2007091624A1 (ja) 2007-08-16
AP2008004576A0 (en) 2008-08-31
AU2007213030A2 (en) 2009-08-27
PT2363463E (pt) 2014-11-18
IL210740A (en) 2014-11-30
DK2363463T3 (da) 2014-12-01
AU2007213030B2 (en) 2013-09-19
MY144455A (en) 2011-09-30
DK2363462T3 (da) 2014-07-14
CN103394096A (zh) 2013-11-20
RU2012108129A (ru) 2013-09-10
TW200804597A (en) 2008-01-16
RU2453603C2 (ru) 2012-06-20
AR059422A1 (es) 2008-04-09
EP2363463B1 (en) 2014-09-17
AU2007213030A1 (en) 2007-08-16
CN101384714A (zh) 2009-03-11
PL2363463T3 (pl) 2015-03-31
IL192681A (en) 2013-07-31
EP1983047A1 (en) 2008-10-22
RU2008136204A (ru) 2010-03-20
TWI477602B (zh) 2015-03-21
JP4171930B2 (ja) 2008-10-29
NO20083376L (no) 2008-11-07
IL192681A0 (en) 2009-02-11
EP2363462A1 (en) 2011-09-07
IL210742A0 (en) 2011-07-31
KR20080099283A (ko) 2008-11-12
AP2880A (en) 2014-05-31
US9023365B2 (en) 2015-05-05
SI2363463T1 (sl) 2015-01-30
IL210742A (en) 2015-01-29
CY1115658T1 (el) 2017-01-25
EP1983047A4 (en) 2009-12-02
BRPI0707646A2 (pt) 2011-05-10
EP2363462B1 (en) 2014-06-18
JPWO2007091624A1 (ja) 2009-07-02
US20100233202A1 (en) 2010-09-16
MX2008010299A (es) 2008-11-14
KR101472924B1 (ko) 2014-12-15
CA2636632C (en) 2015-10-27
IL210740A0 (en) 2011-03-31

Similar Documents

Publication Publication Date Title
ES2520968T3 (es) Nuevo vector baculovírico
Madhan et al. Baculovirus as vaccine vectors
JP2023512648A5 (es)
PE20040560A1 (es) Preparaciones acidas de insulina con estabilidad mejorada
Lin et al. Update on baculovirus as an expression and/or delivery vehicle for vaccine antigens
US20220249648A1 (en) Recombinant baculovirus displaying african swine fever virus proteins, and an immunological composition comprising the same
CN103555766B (zh) 兔出血症病毒样颗粒、其制备方法及应用
JP2005525085A5 (es)
CN1292817A (zh) 新颖重组杆状病毒及其构建方法,以及含该病毒的杀虫组合物
WO2007066334A9 (en) Improved influenza vaccine
ES2723273T3 (es) Vectores poxvirales recombinantes que expresan proteínas de la rabia y OX40 y vacunas fabricadas a partir de los mismos
IL305911A (en) Multifunctional nanoparticle vaccines for influenza
RU2010108248A (ru) Бакуловирусные векторы с двойным промотором, включающим в себя промотор позвоночного и промотор бакуловируса, контролирующим иммуногенный слитый ген
Luo et al. Baculovirus surface display of zika virus envelope protein protects against virus challenge in mouse model
EP1921089A4 (en) PEPTIDE CYTOTOXIC LYMPHOCYTE T EPOPOPY AND USE THEREOF
US20230210980A1 (en) Chimeric adenoviral vectors
EP3916005A2 (en) Immunogenic composition
CN102304529B (zh) 一种兔出血热病毒空衣壳抗原的制备方法
DK1404852T3 (da) Ekspression af gener i modificeret vacciniavirus Ankara ved anvendelse af kokoppe-ATI-promotoren
JP2013512866A5 (es)
AR058049A1 (es) Proteina de la capsida del virus dengue inductora de respuesta protectora y composicion farmaceutica
WO2016059911A1 (ja) マラリアワクチン
CN105671064A (zh) 抗猪繁殖与呼吸综合症病毒感染的重组抗原基因、重组抗原蛋白及亚单位疫苗组合物
Tan et al. Proteomic analyses of the shrimp white spot syndrome virus
ES2194900T3 (es) Peptidos del virus arteritis equina, anticuerpos y su uso en un ensayo diagnostico.